Wikisage, the free encyclopedia of the second generation, is digital heritage

XR-topiramate: Difference between revisions

From Wikisage
Jump to navigation Jump to search
mNo edit summary
(cat)
Line 6: Line 6:


<references/>
<references/>
[[Category:Anticonvulsant]]

Revision as of 23:50, 11 December 2016

Qudexy XR was approved by FDA on March 2014. It is effective on partial onset seisure once daily schedule[1]

Clinical utility of topiramate extended-release capsules (USL255): Bioequivalence of USL255 sprinkled and intact capsule in healthy adults and an in vitro evaluation of sprinkle delivery via enteral feeding tubes


  1. ↑ A review of the efficacy and safety of extended-release topiramate in the adjunctive treatment for refractory partial-onset seizures
Retrieved from "https://en.wikisage.org/w/index.php?title=XR-topiramate&oldid=5295"